

World Journal of Gastroenterology, Manuscript NO: 63067 entitled: "Recent advances in gastro-intestinal cancers", by Bordry et al.

Dear Reviewer,

We thank you for reviewing our manuscript and providing your detailed and highly useful suggestions allowing us to improve our work. Please find below our point-by-point reply [written in blue letters](#).

Reviewer #1 (Remarks to the Author):

This interesting and informative review summarizes 13 phase III studies that were presented at last year's ASCO, ASCO-GI, ESMO and/or ESMO-GI. The manuscript is well written and concise. Minor point might be addressed:

Page 4, NRT-TOG 1010: The sentence "Participants on the experimental treatment arm received weekly trastuzumab during CXRT and then following surgery for 13 treatments." This might be rephrased since treatments is not related to surgery.

[We apologize for not having described the study more clearly. The sentence was changed accordingly: "Participants on the experimental treatment arm received weekly neoadjuvant trastuzumab during CXRT followed by adjuvant trastuzumab for 13 treatments after surgery"](#)

I would suggest to use "esophageal" instead of "oesophageal" throughout the whole manuscript

[We thank the reviewer for his/her suggestions and changed the word "oesophageal" to "esophageal" throughout the entire manuscript.](#)

Results from the IDEA trial should be clarified. Some phrases might be misleading, e.g. "For patients treated with CAPOX 3 months OS was 82.1% compared to 81.2% in those receiving it for 6 months".

[We are sorry for the misunderstanding. We have revised the results from IDEA trial and clarified them. We rephrased some sentences including the one mentioned by the reviewer: "OS was 82.1% for patients treated with 3 months of CAPOX compared to 81.2% in those receiving it for 6 months. In patients treated with FOLFOX, 3 months survival was 82.6% compared to 83.8% for 6 months."](#)

To gain more overview, a summary of the results of the studies in tables might be helpful.

[We thank the reviewer for his/her pertinent comment. We had a Table with the summary of the different study results.](#)